Key result
High-sensitivity C-reactive protein >/L was an independent predictor of cardiovascular mortality in patients with stable congestive heart failure.
Why the study?
Does high-sensitivity C-reactive protein >3 mg/L predict cardiovascular mortality in patients with stable congestive heart failure?
Cohort (n=546)
No
Does high-sensitivity C-reactive protein >3 mg/L predict cardiovascular mortality in patients with stable congestive heart failure?
Elevated hs-CRP (>3 mg/L) is an independent predictor of cardiovascular mortality in patients with stable heart failure, especially those with an ischemic etiology, providing prognostic value beyond BNP and peak VO2.
Answers are grounded in this paper and cite their sources.
May refine prognosis in stable HF beyond BNP; hypothesis-generating and requires trial validation before practice change.
AIMS: To determine the potential adjunct of high-sensitivity (hs) C-reactive protein for risk stratification in patients with stable congestive heart failure (CHF). METHODS AND RESULTS: We studied 546 consecutive patients clinically stable with an ejection fraction <45% who were referred to our centre for evaluation of left ventricular dysfunction. hs C-reactive protein levels were determined on blood samples obtained on entry into the study. Clinical follow-up (median 972 days) was obtained for 545 patients. Cardiovascular mortality was significantly increased (P=0.001) in patients with hs C-reactive protein >3 mg/L. By multivariable analysis, including clinical, biological, and echocardiographic variables, hs C-reactive protein >3 mg/L was an independent predictor of cardiovascular mortality [HR=1.78 (1.17-2.72); P=0.008]; the strongest predictive parameter in this model was B-type natriuretic peptide (BNP) (P=0.005). When peak VO(2) was included into the model, hs C-reactive protein >3 mg/L remained an independent predictor of cardiovascular mortality [HR=1.55 (1.02-2.38); P=0.04]; the strongest predictive parameter in this model was peak VO(2) (P<0.0001). In patients with ischaemic CHF, cardiovascular mortality was significantly increased in patients with hs C-reactive protein >3 mg/L (P=0.001), whereas in patients with non-ischaemic CHF, hs C-reactive protein >3 mg/L was not associated with cardiovascular mortality (P=0.098). By multivariable analysis, hs C-reactive protein >3 mg/L was an independent predictor of cardiovascular mortality in ischaemic patients [HR=2.16 (1.23-3.78)] but not in non-ischaemic patients [HR=1.05 (0.52-2.11)]. CONCLUSION: Cardiovascular mortality is increased in CHF patients with hs C-reactive protein >3 mg/L. The impact of hs C-reactive protein is independent of usual prognostic parameters, in particular BNP and peak VO(2). The interest of hs C-reactive protein determination appears to be especially marked in patients with ischaemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Lamblin et al. (2005) conducted a cohort in Stable congestive heart failure (CHF) (n=546). High-sensitivity C-reactive protein >3 mg/L vs. High-sensitivity C-reactive protein ≤3 mg/L was evaluated on Cardiovascular mortality (HR 1.78, 95% CI 1.17-2.72, p=0.008). High-sensitivity C-reactive protein >/L was an independent predictor of cardiovascular mortality in patients with stable congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: